• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

    2/14/24 10:25:34 AM ET
    $BXRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $BXRX alert in real time by email
    SC 13G/A 1 baudax13ga1-02142024.htm

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13G
    (RULE 13D - 102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)
    (Amendment No. 1)*
    Baudax Bio Inc.
    (Name of Issuer)
    Common Stock, par value $0.01
    (Title of Class of Securities)
    07160F404
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [X]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    (Page 1 of 10)


    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Black Horse Capital LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    0
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    0
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    0
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    0%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    PN



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Black Horse Capital Master Fund Ltd.
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    0
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    0
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    0
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    0%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    CO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Cheval Holdings, Ltd.
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    0
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    0
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    0
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    0%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    CO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Black Horse Capital Management LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    0
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    0
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    0
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    0%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Dale Chappell
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [ ]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Malta
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    0
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    0
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    0
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    0%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    IN, HC


    This Schedule 13G reflects the beneficial ownership of the Reporting Persons (as defined below) as of June 30, 2023.
    Item 1(a).
    Name of Issuer:
    Baudax Bio Inc. (“Issuer”)
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    490 Lapp Road
    Malvern, PA 19355

    Item 2(a).
    Name of Persons Filing:
    This statement is filed by:
    •
    Black Horse Capital LP, a Delaware limited partnership (the “Domestic Fund”),

    •
    Black Horse Capital Master Fund Ltd., a Cayman Islands exempted company ( the “Offshore Fund”),

    •
    Cheval Holdings, Ltd., a Cayman Islands exempted company (“Cheval”),

    •
    Black Horse Capital Management LLC, a Delaware limited liability company (“BH Management”),

    •
    Dale Chappell, a citizen of Malta (Mr. Chappell”).

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
    BH Management is the managing general partner of the Domestic Fund and has been granted by the Board of Directors of Cheval the power to manage the securities of the Issuer owned by Cheval. Mr. Chappell is the managing member of BH Management and the controlling person of the Offshore Fund. By virtue of these relationships, each of BH Management and Mr. Chappell may be deem to beneficially own the shares of the Issuer’s common stock owned directly by each of the Domestic Fund and Cheval and Mr. Chappell may be deemed to beneficially own the Shares owned directly by the Offshore Fund.
    Item 2(b).
    Address of Principal Business Office or, if None, Residence:
    The business address of each of the Domestic Fund, the Offshore Fund, BH Management and Mr. Chappell is c/o Opus Equum, Inc. P.O. Box 788, Dolores, Colorado 81323. The business address of Cheval is P.O Box 309G, Ugland House, Georgetown, Grand Cayman, Cayman Islands KY1-1104.
    Item 2(c).
    Citizenship:
    The Domestic Fund is a Delaware limited partnership.
    Each of the Offshore Fund and Cheval is a Cayman Islands exempt company.
    BH Management is a Delaware limited liability company.
    Mr. Chappell is a citizen of Malta.

    Item 2(d).
    Title of Class of Securities:
    Common Stock, par value $0.01 (“Common Stock”).
    Item 2(e).
    CUSIP Number:
    07160F404
    Item 3.
    If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Exchange Act.
           
     
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Exchange Act.
           
     
    (c)
    [ ]
    Insurance company defined in Section 3(a)(19) of the Exchange Act.
           
     
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act.
           
     
    (e)
    [ ]
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
     
    (f)
    [ ]
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
     
    (g)
    [ ]
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
     
    (h)
    [ ]
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
     
    (i)
    [ ]
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
     
    (j)
    [ ]
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    [ ]
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    If this statement is filed pursuant to Rule 13d-1(c), check this box [ X ]
    Item 4.
    Ownership.
    The percentages used herein and in the rest of this Schedule 13G are for each Reporting Person and have been calculated based upon 43,593,082 Common Shares issued and outstanding as of November 17, 2023 as reported by the Issuer in its Form 10-Q filed with the SEC on November 20, 2023. As of the close of business on December 31, 2023, the Reporting Persons may be deemed to have beneficially owned 0% of Common Stock outstanding.
    (a)
    Amount beneficially owned:

    (a)
    Amount beneficially owned:
    The Domestic fund owns 0 shares of Common Stock.
    The Offshore Fund owns 0 shares of Common Stock.
    Cheval owns 0 shares of Common Stock.
    BH Management may be deemed to beneficially own the shares of Common Stock held by the Domestic Fund and Cheval.
    Mr. Chappell may be deemed to beneficially own the 0 shares of Common Stock held by BH Management and the Offshore Fund.
    Collectively, the Reporting Persons beneficially own 0 shares of Common Stock.


    (b)
    Percent of class:
    The Domestic Fund owns 0 shares of Common Stock representing 0% of the outstanding Common Stock.
    The Offshore Fund owns 0 shares of Common Stock representing 0% of the outstanding Common Stock.
    Cheval owns 0 shares of Common Stock representing 0% of the outstanding Common Stock.
    BH Management beneficially owns 0 shares of Common Stock held by the Domestic Fund and Cheval representing 0% of the outstanding Common Stock.
    Mr. Chappell beneficially owns the 0 shares of Common Stock collectively beneficially owned by BH Management representing 0% of the outstanding Common Stock.

    (c)             (i)             Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or direct the vote:
    The Domestic Fund, BH Management, and Mr. Chappell have the shared power to vote or direct the vote of 0 shares of Common Sttock owned by the Domestic Fund.
    Cheval, BH Management, and Mr. Chappell have the shared power to vote or direct the vote of 0 shares of Common Stock owned by Cheval.
    The Offshore Fund and Mr. Chappell have the shared power to vote or direct the vote of 0 shares of Common Stock owned by the Offshore Fund.

    (iii)
    Sole power to dispose or direct the disposition: 0

    (iv)
    Shared power to dispose or direct the disposition:
    The Domestic Fund, BH Management, and Mr. Chappell have the shared power to dispose or direct the disposition of 0 shares of Common Sttock owned by the Domestic Fund.
    Cheval, BH Management, and Mr. Chappell have the shared power to dispose or direct the disposition of 0 shares of Common Stock owned by Cheval.
    The Offshore Fund and Mr. Chappell have the shared power to dispose or direct the disposition of 0 shares of Common Stock owned by the Offshore Fund.
    Each Reporting Person hereby expressly disclaims beneficial ownership in the securities reported in this Schedule 13G and membership in a “group” as that term is described in Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended.

    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.
    See Exhibit A to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on July 10, 2023.
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
    Item 10.
    Certification.
    The Reporting Persons hereby make the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date: February 14, 2024
     
     
     
    By:
    /s/ Dale Chappell
     
    Dale Chappell
     
    individually and as director of
    Black Horse Capital Master Fund Ltd. and
    Cheval Holdings Ltd., and as managing member of
    Black Horse Capital Management LLC,
    for itself and as the general partner of
    Black Horse Capital LP
     

    * The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

    Get the next $BXRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BXRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BXRX
    SEC Filings

    See more
    • SEC Form 8-K filed by Baudax Bio Inc.

      8-K - Baudax Bio, Inc. (0001780097) (Filer)

      2/28/24 6:15:52 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 25-NSE filed by Baudax Bio Inc.

      25-NSE - Baudax Bio, Inc. (0001780097) (Subject)

      2/15/24 8:53:22 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Inc. filed SEC Form 8-K: Other Events

      8-K - Baudax Bio, Inc. (0001780097) (Filer)

      12/12/23 9:52:05 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Financials

    Live finance-specific insights

    See more
    • Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

      MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distri

      8/23/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Acquires TeraImmune, Inc.

      TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (NASDAQ:BXRX) ("Baudax Bio" or the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases. "This combination blends the world class scientific expertise of the TeraImmune team with

      6/30/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Announces Date of Reconvened Annual Meeting

      MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the "Annual Meeting") without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on June 23, 2023 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2023. The record date for determining shareholders eligible to vote at the Special Meeting will remain the close of business

      6/6/23 9:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      2/14/24 10:25:34 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      2/6/24 11:12:01 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      7/10/23 5:12:03 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Mcandrew Natalie

      3 - Baudax Bio, Inc. (0001780097) (Issuer)

      10/11/23 4:47:44 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 3: New insider Kim Yong Chan claimed ownership of 202,260 shares

      3 - Baudax Bio, Inc. (0001780097) (Issuer)

      7/13/23 4:21:37 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4: Henwood Geraldine bought $3,057 worth of shares (1,200 units at $2.55), increasing direct ownership by 98% to 2,427 units

      4 - Baudax Bio, Inc. (0001780097) (Issuer)

      12/19/22 8:09:42 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baudax Bio Announces Corporate Update

      Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that following recent shareholder approval of corporate actions related to

      10/18/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

      MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company's next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

      9/28/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

      MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY. Gerri Henwood, President & Chief Executive Officer of Baudax Bio, will give a pre-recorded presentation highlighting the Company's cellular therapy progra

      9/7/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth

      Experienced financial executive will build on growth trajectory Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005044/en/Rick Casten, SVP and Chief Financial Officer, Cosette Pharmaceuticals (Photo: Business Wire) "I am excited to have Rick Casten join our team, with his more than two decades of experience in helping drive long term performance gains and financial growth. Rick joins Cosette at a pivotal inflection point

      7/6/22 8:15:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer

      MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro. “I am delighted to welcome Richard to the Baudax team and believe his expertise and leadersh

      3/8/21 7:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care